Perindopril/Indapamide 2/0.625 mg/day: A Review of its Place in the Management of Hypertension

Authors: Matheson A.J.; Cheer S.M.; Goa K.L.

Source: Drugs, Volume 61, Number 8, 2001 , pp. 1211-1229(19)

Buy & download fulltext article:

Price: $68.55 plus tax (Refund Policy)

Abstract:

The fixed low-dose combination of the ACE inhibitor perindopril and the non-thiazide diuretic indapamide has been evaluated in the management of patients with mild to moderate hypertension. Combination therapy aims to improve overall therapeutic efficacy while minimising adverse effects.

In well-designed multicentre clinical trials, perindopril/indapamide at doses ranging from 2/0.625 to 8/2.5 mg/day was significantly more effective than placebo in achieving adequate blood pressure (BP) control. A similar reduction in supine BP was observed when combined perindopril/indapamide 2/0.625 mg/day was compared with losartan 50 mg/day or atenolol 50 mg/day. Similar reductions in 24-hour ambulatory BP were also seen with perindopril/indapamide 2/0.625 mg/day and irbesartan 150 mg/day. However, response and normalisation rates were significantly higher with combination therapy than with losartan or irbesartan monotherapy.

Combined perindopril/indapamide 2/0.625 mg/day therapy effectively reduced BP in elderly patients aged 65 to 85 years to a significantly greater extent than either atenolol 50 mg/day or placebo. Supine BP was also normalised in approximately two-thirds of patients in a small noncomparative trial in patients with hypertension and renal impairment.

Low-dose perindopril/indapamide 2/0.625 mg/day was well tolerated in clinical trials; the most common adverse events were headache and cough. Hypokalaemia, associated with the use of diuretics, occurred with a higher incidence with combined perindopril/indapamide 2/0.625 mg/day therapy than with either atenolol 50 mg/day or placebo.

Perindopril/indapamide 2/0.625 mg/day has shown efficacy in well designed comparative trials with atenolol, losartan and irbesartan including elderly patients and patients with renal impairment. Studies comparing this dosage of perindopril/ indapamide with other combination therapies would be beneficial in allowing the place of perindopril/indapamide to be more accurately determined. The fixed-low dose combination of perindopril/indapamide provides a promising and well tolerated treatment option in the management of patients with mild to moderate hypertension.

Keywords: Antihypertensives, general; Drug evaluations; Elderly; Hypertension, treatment; Perindopril/indapamide, general

Language: English

Document Type: Drug Evaluation

Affiliations: 1: Adis International Limited, Auckland, New Zealand *

Publication date: 2001-01-01

Perindopril/Indapamide 2/0.625 mg/day: A Review of its Place in the Management of Hypertension

Buy & download fulltext article:

Tools

Key

Text size:

Useful pages